Page 41 - Compass Pathways News Today

The conversation began last month when Compass Pathways (NASDAQ:CMPS) introduced a series of patent applications for elements of psilocybin-assisted therapy as basic as using soft furniture, playing music and holding the hand of a patient, as patent lawyer Graham Pechenik noted on Twitter. What seemed like a conversation about securing method patents grew into a larger — and very necessary — debate on whether or not it’s morally acceptable for companies to claim rights on broader aspec...

‘The ketamine blew my mind’: can psychedelics cure addiction and depression? Words: Alexandra Jones Illustration: Frieda Ruh In the summer of 1981, when he was 13, Grant crashed a trail motorbike into a wall at his parents’ house in Cambridgeshire. He’d been hiding it in the shed, but “it was far too powerful for me, and on my very first time starting it in the garden, I smashed it into a wall”. His mother came outside to find the skinny teenager in a heap next to th...

‘The ketamine blew my mind’: can psychedelics cure addiction and depression? ‘We prepare a client for their drug experience; allow them to feel safe and warm.’ Illustration: Frieda Ruh/The Guardian ‘We prepare a client for their drug experience; allow them to feel safe and warm.’ Illustration: Frieda Ruh/The Guardian This week sees the opening of the first UK high-street clinic offering psychedelic-assisted therapy. Could popping psilocybin be the future of menta...

Compass Pathways (NASDAQ:CMPS), the first and only psychedelics company to list on a major U.S. stock exchange, released its financial results for the fourth quarter and year-end 2020. The company is currently recruiting patients for a phase IIb clinical trial of COMP360, a proprietary molecule derived from psilocybin, the active psychedelic found in “magic mushrooms.” Compass is currently leading the way in the path to legalization of psilocybin therapy for treatment-resistant depression....

California’s legislature could soon be discussing a new bill meant to decriminalize psychedelic substances. On Tuesday, State Senator Scott Wiener announced via Twitter his intention to introduce a new bill aimed at pulling back on penalties for the non-commercial use of these drugs, first... Read More... Dont Miss Any Updates! News Directly in Your Inbox Subscribe to:

The Outlaw Chemists Who Deserve a Cut of the Psychedelic Gold Rush They seeded medical breakthroughs and emerging markets. Now expunge their criminal records and let them go legit. Courtesy of the Drug Enforcement Administration A mugshot of William Leonard Pickard On November 6, 2000, Kansas Highway Patrolmen pulled over a rented Buick LeSabre on what seemed like a routine traffic stop. That was until the driver, 58-year-old William Leonard Pickard, bolted from the scene on foot, escaping into...

Heres My List of Billion Dollar Bets Lets look at seven names that you can buy right now and watch grow. Mar 08, 2021 | 12:12 PM EST DMY Technology Group ( DMYI)  announced it would be bringing IonQ public. This will introduce the first quantum computing company to the public markets at an enterprise valuation of $1.38 billion based on $10 per DMYI share. Currently, thats close to $1.6 billion the enterprise metric and a $2.2 billion market cap.   This is definitely a c...

Psychedelics and mental health company The Series D funding round is being touted as the psychedelics sector’s largest to date. Christian Angermayer, who founded Atai in 2018, led the effort with Thiel Capital, the venture capital firm of tech billionaire Peter Thiel. Apeiron Investment Group and Woodline Partners LP also participated. Atai’s portfolio companies are researching 13 different psychedelic and non-psychedelic compounds for the treatment of a wide range of mental health disorde...

Psyched: Atai Raises $157M, Silo Wellness Goes Public, Mydecine Completes Export Of Magic Mushrooms Benzinga 3/8/2021 Psychedelics and mental health company Popular Searches The Series D funding round is being touted as the psychedelics sector’s largest to date. Christian Angermayer, who founded Atai in 2018, led the effort with Thiel Capital, the venture capital firm of tech billionaire Peter Thiel. Apeiron Investment Group and Woodline Partners LP also participated. Atai’s portfolio co...

Significant Progress Made as Numinus-Sponsored PRIME Study on Psilocybin-Assisted Psychotherapy for Opioid, Stimulant and/or Alcohol Use Disorders Enters Pre-Implementation Stage Numinus Wellness (OTC:LKYSD) and  Syreon Corporation, a global contract research organization with expertise in conducting clinical trials across a broad range of diseases, are pleased to share that significant progress has been made in the single-arm, open-label compassionate access1 trial of Psilocybin-Research Int...